CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Experimental drugWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1245 Intracorporeal left hemicolectomy anastomosis Wiki 1.00
drug901 Extracorporeal left hemicolectomy anastomosis Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D003110 Colonic Neoplasms NIH 0.71

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0003003 Colon cancer HPO 0.71

There is one clinical trial.

Clinical Trials


1 A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.

High-throughput screening studies identified Abl kinase inhibitors (including imatinib) as inhibitors of coronaviruses SARS and MERS. The SARS-CoV-2 coronavirus depend on Abl2 kinase activity to fuse and enter into the cells. Pharmacokinetic studies demonstrated that IC50 of imatinib for ABL1, BCR-ABL1 and ABL2 kinase inhibition is less than 1 microM (around 0.3 microM) below the expected trough plasmatic concentrations of imatinib 400 mg/day (1.7 microM). The EC50 of imatinib for the inhibition of the virus is under investigation but we now have a first estimates with EC50 close to 2.5 microM. This plasmatic concentration is achievable with imatinib 800 mg/d. We hypothesize that clinically achievable imatinib concentration will block the first round of cell to cell virus infection and therefore stop or prevent from SARS-CoV-2 infection in human. Based on our 20 years' experience of prescribing imatinib in patients, we expect that most of the adverse events and pharmacological interactions of imatinib can be anticipated and corrected. The eligible population will be aged (>70y) patients hospitalized for a non-severe COVID-19 disease for less than 7 days. Patients will be randomized 1/1 between standard of care and imatinib 800 mg per day during 14 days. The primary endpoint will be the death rate by 30 days. Secondary endpoint will include progression to severe CIVID-19 disease, safety, outcome at 3 months. We plan to randomize 90 patients in order to show a 10% benefit in term of death rate reduction from 16% to 6%.

NCT04357613 SARS Virus Drug: Experimental drug

Primary Outcomes

Description: To evaluate the 30 days mortality rate in aged patients hospitalized with COVID-19

Measure: To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.

Time: 30 days

Secondary Outcomes

Description: Drop out rate of imatinib mesylate therapy

Measure: To evaluate the feasibility of imatinib therapy.

Time: Day 14

Description: Adverse events related to imatinib mesylate therapy

Measure: To evaluate safety of imatinib therapy

Time: 3 months

Description: Clinical (WHO COVID scale) and geriatric scores (GIR, ADL and IADL) modification

Measure: To evaluate the clinical evolution

Time: 3 months

Description: Clinical (WHO COVID scale) and geriatric scores (GIR, ADL and IADL) modification

Measure: To evaluate the progression rate to severe COVID-19 disease

Time: 3 months

Description: number of death

Measure: To evaluate mortality

Time: 14 days

Description: number of death

Measure: To evaluate mortality

Time: 60 days

Description: number of death

Measure: To evaluate mortality

Time: 90 days

Description: Viral load by SARS-CoV-2 PCR

Measure: To evaluate viral load

Time: 14 days

Description: Imatinib trough level

Measure: To evaluate plasmatic levels of imatinib

Time: 14 days


No related HPO nodes (Using clinical trials)